⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
globenewswire.com
IMRX
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
globenewswire.com
IMRX
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)
businesswire.com
BCYC
IMRX
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
prnewswire.com
ONCY
IMRX
TNGX
MRNA
RPRX
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
IMRX
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
globenewswire.com
IMRX
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
globenewswire.com
IMRX
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
globenewswire.com
IMRX
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
globenewswire.com
IMRX